

**AMENDED CLAIMS**

[received by the International Bureau on 14 March 2005 (14.03.05);  
claims 1-7 amended, claim 8 added]

1. An ophthalmic solution comprising 0.001 to 10 weight percent of a preservative enhancer chosen from the group consisting of peptides D4E1, and D2A21, [and P-113;] and at least 0.0001 weight percent of a second agent, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
2. The ophthalmic solution of claim 1, wherein the concentration of said [cationic] polymeric preservative is between 1 and 100 parts per million.
3. The ophthalmic solution of claim 2, further comprising a physiologically compatible buffer selected from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, TRIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, Tris, MES, MOPS, PIPES, TES, Glycine and Tricine.
4. The ophthalmic solution of claim 3, further comprising between 0.01% and 5.0% glycerin.
5. The ophthalmic solution of claim 1 further comprising between 0.01% and 2.0% of decanedioic acid.
6. The ophthalmic solution of claim 1 further comprising a wetting agent selected from the group consisting of polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils.
7. The ophthalmic solution of claim 1 further comprising a sequestering agent selected from the group consisting as ethylenediaminetetraacetic acid, phosphonates, citrate, gluconate and tartarate.
8. An ophthalmic solution comprising 0.001 to 1.5 weight percent of the preservative enhancer P-113 and at least 0.001 weight percent of a second preservation agent.